31년 2023월 XNUMX일에 종료된 XNUMX개월 간의 중간 결과
알레르기 치료 plc
("알레르기 치료제" 또는 "당사" 또는 "그룹")
31년 2023월 XNUMX일에 종료된 XNUMX개월 동안의 중간 결과
Significant clinical and regulatory progress
Financial turnaround on track. Strengthened balance sheet and restructuring plan paves the way to future growth.
- Primary end point met in G306 Pivotal Study for Grass Allergic Patients
- Successful development of VLP Peanut vaccine program underpins the phase I/IIa study.
27년 2024월 XNUMX일: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2023.
하이라이트
재정상의
- Completion of the subscription and open offer (the "Equity Financing") to restructure the Group's balance sheet, enhancing financial stability with net assets increasing to £26.5m
- Implementation of ongoing cost reduction strategy, reducing the Group's overheads pre-R&D by 14.9%
- Increased investment in R&D pipeline, demonstrating the Group's commitment to innovation and the development of allergy immunotherapies
조작상의
- Primary endpoint of the Group's pivotal Phase III G306 trial for Grass MATA MPL met and discussions with regulators ongoing ahead of planned market authorisation application
- Subcutaneous dosing of peanut allergic patients has begun in the Phase I/IIa PROTECT trial
- Group continues to focus on high value growth products to enhance future profitability
포스트 기간
- The first £7.5m of the existing £40m Amended Loan Facility (defined below) drawn down from ZQ Capital and Southern Fox (the "Lenders")
- Successful discussions with the Lenders have led to an agreement for a further £15m of the £40m Amended Loan Facility to be drawn down during Q2 calendar year 2024
Manuel Llobet, CEO at Allergy Therapeutics, stated: 2023 has been an important year, marked by a highly focused approach to our business priorities, and a steadfast commitment to our Grass and Peanut allergy R&D programmes. We have navigated the challenges of last year, resulting in more streamlined operations and improved cost-effectiveness. This progress starts to pave the way towards a return to growth.
The successful completion of the pivotal Phase III G306 trial for Grass MATA MPL, meeting its primary endpoint, and the continuous clinical advancements in our VLP Peanut R&D programme, are a testament to our innovative capabilities. The progress in the development of these two treatments reaffirms the purpose of our work, to transform the lives of people with allergies and those around them.
None of this could have been achieved without the resilience, commitment, and passion of our R&D team, all employees across the Group and our Board. I am proud of the progress the Company has made in a difficult year.
Finally, thank you to our shareholders who have remained supportive of the Company throughout the period, including in the Equity Financing completed in October.
재무 검토
Revenue for the six months ended 31 December 2023 was £33.6m (2023 H1: £39.9m) representing a reduction of 16% on a reported and constant currency basis. This decrease in revenue is due to the previously reported manufacturing capacity that needed to be allocated to investigational medicinal product batches for use in clinical trials and the ongoing programme of continuous improvement across the supply chain and quality systems paving the way for increased capacity. Demand for the Company's products continues to be robust with the revenue achieved being limited by manufacturing capacity constraints. As previously announced a further increase in investment in plant and equipment is also planned to support the continuing improvements in manufacturing and quality which will be a multi-year investment. The focus has been on higher value products and markets, which are expected to enhance future profitability.
Cost of sales reduced to £13.1m (2023 H1: £14.1m) as a consequence of the reduced volumes allocated to manufacturing commercial sales batches.
Sales, marketing and distribution costs were lower than the prior period at £10.2m (2023 H1: £13.2m) mainly as a result of reduced marketing and promotional activity. Administrative expenses reduced to £11.1m (2023 H1: £11.9m) due to continued cost control initiatives. Exceptional costs were £0.4m (2023 H1: £0.4m) as a result of the ongoing review of funding options.
The operating loss pre-R&D and exceptional costs was £0.1m (2023 H1: £1.0m operating profit pre-R&D and exceptional costs). This loss was mitigated by the successful efforts to reduce distribution and administrative costs through cost control initiatives implemented over the past year.
Research and development costs increased to £11.4m (2023 H1: £8.5m) mainly due to the Group's pivotal G306 Phase III trial of Grass MATA MPL which successfully met its primary endpoint as previously announced on 14 November 2023.
The operating loss was £11.9m (2023 H1: £8.0m), and the loss before tax was £14.9m (2023 H1: £8.2m). The tax charge of £0.7m (2023 H1: £0.3m) relates to the overseas subsidiaries.
At 31 December 2023, the Group had cash of £13.5m (30 June 2023: £14.8m) and debt of £1.6m (30 June 2023: £27.1m). This debt reduction was achieved through the successful completion of the Equity Financing to restructure the Group's balance sheet.
The operating cash outflow was £10.8m and investing outflow £1.8m, offset by a net inflow of £11.2m from the net proceeds of the issue of equity shares and repayment of shareholder loans.
The Company completed the £40.75m Equity Financing on 13 October 2023, proceeds of which were used to repay amounts drawn at that time under the original loan facility ("Loan Facility") arranged with the Lenders.
The Loan Facility agreement was amended twice (the "Amended Loan Facility"), as first announced in a circular on 27 September 2023 and subsequently on 27 December 2023.
The Amended Loan Facility provides £40m available to be drawn down from 15 January 2024 until 15 January 2026 with interest payable semi-annually at 12 per cent. per annum and a repayment date of 15 January 2027. Under the attached warrant instrument, on each drawdown under the Amended Loan Facility the Lenders are issued 25 warrants for each £1 drawn down up to a maximum of 1,000,000,000 warrants. The warrants entitle the holders to subscribe for new ordinary shares at a price of 4 pence per share and are exercisable in whole or in part from 1 July 2024 until 15 January 2027.
£7.5m is currently drawn down under the Amended Loan Facility. The Lenders and the Company have also agreed to a further drawdown of £15m from the Amended Loan Facility, expected during April 2024. Following this drawdown, the Group expects that additional funding will be required during Q1 FY2025 for trading, working capital, capital expenditure and continuing R&D programmes.
XNUMXD덴탈의 Directors have applied the going concern principle in preparing the interim results for the six months ended 31 December 2023, however there is material uncertainty due to the need for additional near-term funding and the balance of the Amended Loan Facility currently being uncommitted.
R&D 프로그램 업데이트
The Group announced in December 2023 the positive primary and secondary endpoint outcomes of the G306 pivotal Phase III trial investigating Grass MATA MPL. This pivotal Phase III trial assessed efficacy of the Group's wholly owned short-course grass pollen immunotherapy, Grass MATA MPL.
The data gathered was highly consistent with that seen in prior trial data. The Group is collating a full data package for regulatory submission and discussions with regulators ahead of planned market authorisation application are ongoing. The Group expects to be the first company to register SCIT Grass immunotherapy under the Therapie Allergene Verordnung (TAV) programme.
Preparations are also ongoing for the initiation of the G308 combined short-term and long-term paediatric clinical trial that is due to commence in Q2 2024. This trial is designed to support a paediatric indication for the Group's Grass MATA MPL product and to also provide long-term efficacy and disease modifying data. This trial will meet the previously communicated requirements of Paediatric Committee for a paediatric registration in Germany.
The VLP Peanut R&D programme is further advancing and in March 2024 the Group announced that subcutaneous dosing of peanut allergic patients had begun in the Phase I/IIa PROTECT trial without any relevant safety issues. The PROTECT trial is designed to evaluate the novel virus-like particle (VLP)-based peanut allergy vaccine candidate ("VLP Peanut").
The PROTECT trial is being executed in the US and conducted in both healthy volunteers and peanut allergic patients and consists of Part A and Part B.
· Part A of the clinical trial is open-label and involves ascending doses of subcutaneous immunotherapy (SCIT) dosing of VLP Peanut in healthy volunteers (Group A1) and skin-prick testing in peanut allergic patients (Group A2).
· Part B of the clinical trial is double-blind, placebo-controlled and is being conducted in subjects with peanut allergy. Part B includes an innovative biomarker part to support clinical proof of concept, in collaboration with the renowned allergy laboratories at Johns Hopkins University (US) and Imperial College (UK).
Dosing in Group A2 of PROTECT was recently completed and results have been well-received in scientific forums and are submitted for publication in the prestigious Journal of Allergy and Clinical Immunology. Part A1 has progressed well, with 2 cohorts of healthy subjects having successfully completed up-dosing up to 25-fold the starting dose. Following an external safety review committee, it was determined that it was safe to proceed with incremental subcutaneous dosing in healthy subjects in subsequent cohorts and to start dosing in peanut allergic patients in the Phase IIa part of the trial (Group B).
Outlook
In the second half of the financial year, sales are expected to be slightly higher than the previous year. Consequently, overall sales for the full year ending on 30 June 2024 are expected to be slightly lower than the corresponding period ending 30 June 2023. The Group will continue with cost control initiatives but will undertake selective investments such as the programme of continuous improvement across the supply chain and quality systems paving the way for increased capacity. This is an ongoing multi-year project.
The Group's R&D programmes, including the G306 Phase III trial, the upcoming G308 paediatric clinical trial, and the PROTECT trial, continue to progress the Company's efforts towards its strategic goals of strengthening our pipeline and expanding in Europe.
The ongoing discussions surrounding further funding, coupled with the financing provided by our major shareholders under the Amended Loan Facility underline the confidence held in the Group and the future potential that can be leveraged from the R&D pipeline. The Group is planning for success, and preparations are underway for relevant health authority submissions that will support the unmet need in the market for allergic patients.
이 발표에는 영국 시장 남용 규정의 목적을 위한 내부 정보가 포함되어 있습니다.
- 종료 -
자세한 내용은 문의하시기 바랍니다 :
알레르기 치료제
마누엘 로벳(Manuel Llobet) 최고경영자(CEO)
Shaun Furlong, 최고 재무 책임자
+44 (0)1903 845 820
Panmure Gordon(지명 고문 및 Broker)
Emma Earl, Freddy Crossley, Mark Rogers, 기업 금융
Rupert Dearden, 기업 중개
+44 (0)20 7886 2500
ICR 콘실리움
메리 제인 엘리엇 / 데이빗 데일리 / 데이빗 살비
+44 (0)20 3709 5700
알레르기 치료제에 대하여
Allergy Therapeutics는 영국에 본사를 두고 있는 국제 상업 생명공학 회사로, 질병을 치료할 수 있는 가능성이 있는 무알루미늄 면역요법 백신을 포함하여 알레르기 질환의 치료 및 진단에 중점을 두고 있습니다. 그룹은 XNUMX개의 주요 유럽 국가에 있는 자회사와 추가 XNUMX개 국가에서 유통 계약을 통해 독점 및 제XNUMX자 제품을 판매합니다. 임상 개발 중인 광범위한 제품 파이프라인에는 잔디, 나무, 집 먼지 진드기 및 땅콩에 대한 백신이 포함됩니다. 자세한 내용은 다음을 참조하십시오. www.allergytherapeutics.com.
알레르기 치료제 PLC | |||
| |||
연결 손익 계산서 | |||
6 개월 ~ | 6 개월 ~ | 12 개월 ~ | |
31 12 월 2023 | 31 12 월 2022 | 6월 30 2023 | |
£'000 | £'000 | £'000 | |
감사되지 않음 | 감사되지 않음 | 감사 | |
수익 | 33,572 | 39,901 | 59,587 |
매출원가 | (13,052) | (14,118) | (26,342) |
매출 총 이익 | 20,520 | 25,783 | 33,245 |
판매, 마케팅 및 유통 비용 | (10,222) | (13,237) | (23,705) |
관리비 | (11,138) | (11,863) | (25,179) |
연구 및 개발 비용 | (11,386) | (8,498) | (20,121) |
Exceptional costs - adjustment to provision | - | - | (2,069) |
Exceptional fundraising costs | (420) | (424) | (2,681) |
다른 수입 | 760 | 282 | 856 |
운영 손실 | (11,886) | (7,957) | (39,654) |
금융 수입 | 159 | 155 | 329 |
재정 비용 | (3,189) | (398) | (2,441) |
세전 손실 | (14,916) | (8,200) | (41,766) |
소득세 | (735) | (306) | (1,305) |
해당 기간 동안의 손실 | (15,651) | (8,506) | (43,071) |
주당 손실 | |||
기본(주당 펜스) | (0.58:XNUMX)p | (1.29:XNUMX)p | (6.43:XNUMX)p |
희석(주당 펜스) | (0.58:XNUMX)p | (1.29:XNUMX)p | (6.43:XNUMX)p |
연결포괄손익계산서 | |||
6 개월 ~ | 6 개월 ~ | 12 개월 ~ | |
| 31 12 월 2023 | 31 12 월 2022 | 6월 30 2023 |
| £'000 | £'000 | £'000 |
| 감사되지 않음 | 감사되지 않음 | 감사 |
| |||
해당 기간 동안의 손실 | (15,651) | (8,506) | (43,071) |
차후 당기손익으로 재분류되지 않는 항목: | |||
순확정급여부채의 재측정 | (749) | 479 | 603 |
투자-퇴직급여자산의 재측정 | 324 | 661 | (867) |
재평가 이익 - 프리홀드 토지 및 건물 | - | - | 428 |
기타포괄손실총계 | (425) | 1,140 | 164 |
후속 적으로 당기 손익으로 재 분류 될 수있는 항목 : | |||
해외사업장 환산차이 | 392 | 414 | 193 |
총 포괄 손실 | (15,684) | (6,952) | (42,714) |
알레르기 치료제 PLC | |||
연결 대차 대조표 | |||
31 12 월 2023 | 31 12 월 2022 | 6월 30 2023 | |
£'000 | £'000 | £'000 | |
감사되지 않음 | 감사되지 않음 | 감사 | |
자산 | |||
비유동 자산 | |||
재산, 식물 및 장비 | 23,392 | 22,096 | 23,241 |
무형 자산 - 영업권 | 3,364 | 3,407 | 3,346 |
무형자산 - 기타 | 1,626 | 1,202 | 1,790 |
투자 - 퇴직급여자산 | 5,346 | 7,042 | 4,866 |
비유동 자산 | 33,728 | 33,747 | 33,243 |
유동 자산 | |||
재고 | 11,893 | 10,971 | 11,593 |
매출 채권 및 기타 채권 | 9,934 | 11,697 | 7,088 |
현금 및 현금성 자산 | 13,522 | 15,197 | 14,845 |
총 유동 자산 | 35,349 | 37,865 | 33,526 |
총자산 | 69,077 | 71,612 | 66,769 |
부채 | |||
유동 부채 | |||
매입 채무 및 기타 채무 | (20,088) | (14,299) | (16,683) |
현재 차입금 | (635) | (775) | (648) |
리스 부채 | (1,115) | (1,132) | (1,155) |
식량 | (3,434) | - | - |
파생 금융 상품 | - | (847) | (79) |
총 유동 부채 | (25,272) | (17,053) | (18,565) |
순유동 자산 | 10,007 | 20,812 | 14,961 |
비유동 부채 | |||
퇴직금 의무 | (8,685) | (8,179) | (7,917) |
이연과세부채 | (463) | (402) | (454) |
식량 | (95) | (152) | (3,581) |
리스 부채 | (7,152) | (6,669) | (7,747) |
장기 차입금 | (948) | (1,199) | (26,439) |
비유동 부채 | (17,343) | (16,601) | (46,138) |
총 부채 | (42,615) | (33,654) | (64,703) |
순자산 | 26,462 | 37,958 | 2,066 |
공평 | |||
자본 및 준비금 | |||
발행된 자본금 | 4,776 | 689 | 689 |
프리미엄 공유 | 154,672 | 119,029 | 119,030 |
합병준비금 | 40,128 | 40,128 | 40,128 |
준비금 - 주식 기반 지불 | - | 2,824 | 2,906 |
재평가 적립금 | 1,501 | 1,073 | 1,501 |
Reserve - warrants | 412 | - | 412 |
외환 준비금 | (338) | (509) | (730) |
이익 잉여금 | (174,689) | (125,276) | (161,870) |
총 자본 | 26,462 | 37,958 | 2,066 |
| 알레르기 치료제 PLC
연결자본변동표
| |||||||||
| 발행주식 자본금 | 프리미엄 공유 | 합병준비금 | 준비금 - 주식 기반 지불 |
재평가 적립금
|
예약하다 - 영장 | 외환 준비금 | 이익 잉여금
| Total equity
| |
| £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | |
31년 2022월 XNUMX일 | 689 | 119,029 | 40,128 | 2,824 | 1,073 |
- | (509) | (125,276) | 37,958 | |
해외사업장 환산차이 | - | - | - | - | - |
- | (221) | - | (221) | |
자본(토지 및 건물)에 대한 평가 이익 - 이연 법인세 차감 | - | - | - | - | 428 |
- | - | - | 428 | |
순확정급여부채의 재측정 | - | - | - | - | - |
- | - | 124 | 124 | |
투자재측정 - 퇴직급여자산 | - | - | - | - | - |
- | - | (2,160) | (2,160) | |
기타포괄손실총계 | - | - | - | - | 428 |
- | (221) | (2,036) | (1,829) | |
세금 후 기간의 손실 | - | - | - | - | - |
- | - | (34,565) | (34,565) | |
총 포괄 손실 | - | - | - | - | 428 |
- | (221) | (36,601) | (36,394) | |
공유 기반 지불 | - | - | - | 89 | - |
- | - | - | 89 | |
발행주식수 | - | 1 | - | - | - |
- | - | - | 1 | |
소멸된 옵션 양도 to retained earnings | - | - | - | (7) | - |
- | - | 7 | - | |
영장 발부 | - | - | - | - | - |
412 | - | - | 412 | |
30년 2023월 XNUMX일 | 689 | 119,030 | 40,128 | 2,906 | 1,501 |
412 | (730) | (161,870) | 2,066 | |
해외사업장 환산차이 | - | - | - | - | - |
- | 392 | - | 392 | |
순확정급여부채의 재측정 | - | - | - | - | - |
- | - | (749) | (749) | |
투자재측정 - 퇴직급여자산 | - | - | - | - | - |
- | - | 324 | 324 | |
기타포괄손실총계 | - | - | - | - | - |
- | 392 | (425) | (33) | |
세금 후 기간의 손실 | - | - | - | - | - |
- | - | (15,651) | (15,651) | |
총 포괄 손실 | - | - | - | - | - |
- | 392 | (16,076) | (15,684) | |
공유 기반 지불 | - | - | - | 351 | - |
- | - | - | 351 | |
소멸된 옵션을 이익잉여금으로 이전 | - | - | - | (3,257) | - |
- | - | 3,257 | - | |
발행주식수 | 4,087 | 36,672 | - | - | - |
- | - | - | 40,759 | |
발행 비용 공유 | - | (1,030) | - | - | - |
- | - | - | (1,030) | |
31년 2023월 XNUMX일 | 4,776 | 154,672 | 40,128 | - | 1,501 |
412 | (338) | (174,689) | 26,462 | |
알레르기 치료제 PLC | ||||
| ||||
연결 현금 흐름표 | ||||
6 개월 ~ | 6 개월 ~ | 12 개월 ~ | ||
31 12 월 2023 | 31 12 월 2022 | 6월 30 2023 | ||
£'000 | £'000 | £'000 | ||
감사되지 않음 | 감사되지 않음 | 감사 | ||
영업 활동으로 인한 현금 흐름 | ||||
세전 손실 | (14,916) | (8,200) | (41,766) | |
다음에 대한 조정 : | ||||
금융 수입 | (159) | (155) | (329) | |
재정 비용 | 3,189 | 398 | 2,441 | |
| 확정 급여 연금 제도의 비현금 이동 | (160) | (142) | (79) |
| 감가상각 및 상각 | 2,114 | 2,102 | 4,224 |
| R&D 세금 공제 한도 초과의 순 금전적 가치 | (760) | (282) | (856) |
| 주식 기준 지불에 대한 수수료 | 351 | 25 | 114 |
| 퇴직금 투자금 지급 | - | - | (159) |
| 파생금융상품의 공정가치 변동 | (79) | 731 | (37) |
| 매출채권 및 기타수취채권의 (증가)/감소 | (3,307) | (1,042) | 3,380 |
| (증가) 재고 | (255) | 611 | (183) |
| 거래 및 기타 미지급금의 증가 | 3,174 | (1,405) | 4,818 |
| ||||
| 영업에 사용된 순 현금 | (10,808) | (7,359) | (28,432) |
| ||||
| 소득세 수령/(납부) | 34 | (92) | (449) |
| ||||
| 영업 활동에 사용 된 순 현금 | (10,774) | (7,451) | (28,881) |
| ||||
| 투자 활동으로 인한 현금 흐름 | |||
| 받은이자 | 69 | 18 | 82 |
| 무형 자산에 대한 지불 | - | (630) | - |
| 부동산 공장 및 장비에 대한 지불 | (1,865) | (2,255) | (4,669) |
| ||||
| 투자 활동에 사용 된 순 현금 | (1,796) | (2,867) | (4,587) |
| ||||
| 금융 활동으로 인한 현금 흐름 | |||
| 주식 발행 순수익 | 39,731 | 6,488 | 6,489 |
| 은행 대출금 상환 | (333) | (533) | (961) |
| Interest paid on loan borrowings | (1,646) | (137) | (2,117) |
| 리스부채의 원금상환 | (409) | (761) | (1,281) |
| 리스부채에 대한 이자 | (159) | (160) | (334) |
| Proceeds from shareholder loan | 14,075 | - | 36,000 |
| 주주대출 상환 | (40,075) | - | (10,000) |
| ||||
| 재무활동으로 발생한 순현금 | 11,184 | 4,897 | 27,796 |
| ||||
| 현금 및 현금 등가물의 순 감소 | (1,386) | (5,421) | (5,672) |
| 환율이 현금 및 현금 등가물에 미치는 영향 | 63 | 103 | 2 |
| 기초의 현금 및 현금성자산 | 14,845 | 20,515 | 20,515 |
| ||||
| 기말의 현금 및 현금 등가물 | 13,522 | 15,197 | 14,845 |
1. 중간재무제표
감사되지 않은 연결 중간 재무 정보는 31년 2023월 30일에 종료되는 2023개월에 대한 것입니다. 재무 정보에는 전체 연간 재무제표에 필요한 모든 정보가 포함되어 있지 않으며 2006년에 종료되는 연도의 연결 재무제표와 함께 읽어야 합니다. XNUMX년 XNUMX월, 이는 영국이 채택한 IFRS(International Financial Reporting Standards) 및 영국에서 채택한 IFRS에 따라 계정을 준비하는 그룹과 관련된 회사법 XNUMX의 해당 부분에 따라 작성되었습니다.
중간 재무 정보는 감사관행위원회의 ISRE 2410에 따라 감사되거나 검토되지 않았습니다. 이 중간 보고서에 명시된 재무 정보는 회사법 434의 섹션 2006에 정의된 법정 계정을 구성하지 않습니다.
2. 준비의 기초
허용되는 경우 이 중간 보고서는 IAS 34 "중간 재무 보고"가 아닌 AIM 규칙에 따라 작성되었습니다. 이 보고서에서 채택된 회계 정책은 30년 2023월 XNUMX일까지의 연차 재무제표의 정책과 일치합니다. 재무제표에 중대한 영향을 미칠 현재 기간에 발효된 회계 기준은 없습니다.
관심가는
이 재무제표는 재무제표 승인일로부터 최소 12개월 동안 그룹과 회사의 현재 현금상태를 고려하고 예산 및 현금흐름 예측을 검토한 후 계속기업 기준으로 작성되었습니다.
On 27 December the Group announced a second amendment to the Amended Loan Facility which provided for a £40m loan facility of which £7.5m would be initially committed, the remaining £32.5m uncommitted. The committed portion, being £7.5m, was drawdown in Q1 calendar year 2024. Successful discussions with the Lenders, post period, have led to an agreement for a further £15m of the £40m Amended Loan Facility to be drawn down during Q2 calendar year 2024. Interest accrues on the loan at 12% per annum with interest payments due every 6 months. Full repayment of the interest and principal is due by 15 January 2027.
The Directors have prepared cash flow forecasts for the period to 30 June 2025, which assume that the Group will be able to undertake additional financing activities. £7.5 million is currently drawn under the Amended Loan Facility. Following future drawdown of the recently agreed further £15m from the Amended Loan Facility, the Group expects that additional funding will be required during Q1 FY2025 onwards for trading, working capital, capital expenditure and continuing R&D programmes. The remaining uncommitted portion of the Amended Loan Facility, should it become committed, would provide sufficient funds for the 12-month going concern review period.
The Directors acknowledge that a material uncertainty exists over the Group's ability to access additional sources of finance, which will be required to fund trading, working capital, capital expenditure and continuing R&D programme.
The Directors have reasonable expectations that additional financing can be obtained for the Group and Company. Accordingly, they have prepared these financial statements on a going concern basis.
3. 주당손실
6 개월 ~ | 6 개월 ~ | 12 개월 ~ | |
31 12 월 2023 | 31 12 월 2022 | 6월 30 2023 | |
감사되지 않음 | 감사되지 않음 | 감사 | |
Loss after tax attributable to equity shareholders (£'000) | (15,651) | (8,506) | (43,071) |
기초 보통주 발행액('000) | 679,105 | 644,105 | 644,105 |
기간('000)에 발행된 보통주 | 4,087,335 | 35,000 | 35,000 |
기말 보통주 발행액 ('000) | 4,766,440 | 679,105 | 679,105 |
해당 기간의 가중평균 발행주식수 | 2,720,224 | 661,605 | 670,355 |
희석 이익에 대한 가중 평균 주식수 | 2,720,224 | 661,605 | 670,355 |
보통주당 기본 수익(펜스) | (0.58:XNUMX)p | (1.29:XNUMX)p | (6.43:XNUMX)p |
희석 보통주당 이익(펜스) | (0.58:XNUMX)p | (1.29:XNUMX)p | (6.43:XNUMX)p |
2023년의 희석주당손실은 주식선택권의 행사가 주당손실을 감소시키는 효과가 있으므로 IAS 33의 조건에 따라 희석적이지 않기 때문에 기본주당손실과 다르지 않습니다.
4. 대차대조표일 이후의 사건
There were no disclosable events after the balance sheet date other than the drawdown of funds and agreement for further drawdown discussed in note 2 to the unaudited consolidated interim financial information above.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.